Drug intelligence / Profile preview

human fibrinogen albumin microspheres

Development stage
Phase 2
Lead developer
Kuaiyi Biopharmaceutical Technology
Modality
Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

**Human fibrinogen albumin microspheres** is an investigational intravenous platelet-substitute biologic developed by Kuaiyi Biopharmaceutical Technology for refractory thrombocytopenia. The product comprises human serum albumin microspheres bearing human fibrinogen on their surface. Surface fibrinogen is intended to bind platelet integrin alpha-IIb/beta-3, enabling the microspheres to bridge residual native platelets and promote platelet adhesion and aggregate formation to support hemostasis in patients with severe thrombocytopenia. The product, also called Fiplatezin, has been evaluated in a Phase III Chinese study following Phase IIb development.

Brand names
Shuyang Yinyuan
Other names
Fiplatezinfibrinogen-albumin microspheresfreeze-dried human fibrinogen albumin microsphereslyophilized human fibrin-albumin microsphereslyophilized human fibrinogen-albumin microspheres
02

Targets

GPIIb/IIIa (Integrin alpha-IIb/beta-3)

Beyond the preview

Go deeper on human fibrinogen albumin microspheres.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human fibrinogen albumin microspheres.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call